Acasti Pharma (ACST) News Today $3.37 -0.03 (-0.88%) (As of 10/25/2024) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Annexon (NASDAQ:ANNX) and Acasti Pharma (NASDAQ:ACST) Critical ReviewNovember 19 at 2:57 AM | americanbankingnews.comAcasti Pharma changes name to Grace TherapeuticsOctober 26, 2024 | msn.comAcasti Announces Corporate Name Change to Grace Therapeutics, Inc.October 25, 2024 | globenewswire.comCraig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)September 27, 2024 | markets.businessinsider.comAcasti Pharma, Inc.: Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104September 25, 2024 | finanznachrichten.deAcasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104September 25, 2024 | globenewswire.comAcasti to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comAcasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business UpdateAugust 9, 2024 | globenewswire.comACST Acasti Pharma Inc.July 24, 2024 | seekingalpha.comAcasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety TrialJune 27, 2024 | globenewswire.comACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024June 21, 2024 | investorplace.comAcasti Announces Year-End 2024 Financial Results, Provides Business UpdateJune 21, 2024 | globenewswire.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024June 18, 2024 | investorplace.comAcasti Pharma to Attend BIO International Convention 2024May 28, 2024 | globenewswire.comThe Next Novavax? 3 Biopharma Stocks to Buy Before They BoomMay 23, 2024 | investorplace.comInsider Stock Buying Reaches US$2.50m On Acasti PharmaMay 21, 2024 | finance.yahoo.comAcasti Pharma (NASDAQ: ACST)May 5, 2024 | fool.comAcasti Pharma Inc Class ADecember 14, 2023 | morningstar.comAcasti to Participate in Upcoming San Francisco Investor Conferences in January 2024December 13, 2023 | finance.yahoo.comAcasti Announces Second Quarter 2024 Financial Results and Business HighlightsNovember 13, 2023 | finance.yahoo.comOptimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage TreatmentOctober 18, 2023 | markets.businessinsider.comAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)October 4, 2023 | finance.yahoo.comAcasti announces $7.5M private placement equity fundingSeptember 27, 2023 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)July 12, 2023 | markets.businessinsider.comTrading was temporarily halted for "ACST" at 10:07 AM with a stated reason of "LULD pause."July 10, 2023 | marketbeat.comAcasti Pharma: Reverse Stock Split To Become Effective July 10July 7, 2023 | markets.businessinsider.comAcasti Pharma Announces 1-for-6 Reverse Stock SplitJuly 7, 2023 | finance.yahoo.comAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023July 5, 2023 | finance.yahoo.comRecap: Acasti Pharma Q4 EarningsJune 23, 2023 | msn.comWe're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash WiselyMay 10, 2023 | finance.yahoo.comAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025May 8, 2023 | finance.yahoo.comAcasti Announces Appointment of Prashant Kohli as CEOApril 4, 2023 | finance.yahoo.comAcasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDApril 4, 2023 | finance.yahoo.comWhen Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?March 30, 2023 | finance.yahoo.comAcasti Pharma Inc. Announces the Resignation of a DirectorMarch 30, 2023 | finance.yahoo.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangeMarch 13, 2023 | finance.yahoo.comAcasti Pharma's Earnings OutlookFebruary 13, 2023 | msn.comAcasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023February 7, 2023 | finance.yahoo.comAcasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price RuleJanuary 25, 2023 | finance.yahoo.comAcasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day PodcastJanuary 17, 2023 | finance.yahoo.comAcasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome MeasuresJanuary 5, 2023 | finance.yahoo.comH.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)December 29, 2022 | markets.businessinsider.comAcasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call TranscriptDecember 29, 2022 | finance.yahoo.comAcasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia TelangiectasiaDecember 28, 2022 | finance.yahoo.comAcasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)December 22, 2022 | finance.yahoo.comAcasti Pharma Reports Second Quarter 2023 Operational ResultsNovember 14, 2022 | financialpost.comAcasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022November 8, 2022 | finance.yahoo.comAcasti Announces Voting Results from 2022 Annual and Special Meeting of ShareholdersSeptember 29, 2022 | finance.yahoo.comAcasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day PodcastSeptember 21, 2022 | finance.yahoo.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia TelangiectasiaSeptember 13, 2022 | finance.yahoo.com Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. ACST Media Mentions By Week ACST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACST News Sentiment▼-0.710.46▲Average Medical News Sentiment ACST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACST Articles This Week▼10▲ACST Articles Average Week Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADVM News CDTX News PLX News OTLK News CRDL News RPTX News VTYX News IFRX News CHRS News PYXS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACST) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACST Stock Alerts